iSono Health is a commercial-stage medical technology company focused on transforming women’s breast imaging with ATUSA™, an FDA-cleared, portable and hands-free 3D ultrasound platform. The system captures full-breast volumes in about two minutes per breast—roughly ten times faster than manual handheld ultrasound—and delivers consistent images independent of the operator’s skill. By pairing its wearable hardware with cloud-based intelligence, the company offers an "Ultrasound-as-a-Service" model that lowers upfront costs for clinics and generates recurring revenue. iSono is advancing an AI "sentient partner" roadmap to provide real-time diagnostic support and is running the 800-patient, NIH-funded AUDIBLE Study to validate its algorithms against mammography and MRI. The company has secured multiple paying clinics through a Pioneering Partner Program and earned industry recognition such as HLTH 2025 Rising Star (Diagnostics) and WISH 2024 Global Awards. Financially, iSono has raised $14.7 million across venture rounds and non-dilutive grants, including a recent $3 million Seed Preferred round and $3.7 million from NIH, NSF and NCI. These funds position the firm to scale global deployments while continuing clinical validation.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2026